论文部分内容阅读
抗肿瘤药物具有治疗指数低,安全范围窄等特点,临床用药过程中易出现毒副作用,限制其使用。近年来,一些研究指出抗肿瘤药物不良反应的发生机制与药物代谢酶、受体和转运体有关,其中药物代谢酶及其基因多态性在抗肿瘤药物代谢过程中产生的毒副反应起着举足轻重的作用。笔者就目前临床上由药物代谢酶介导的抗肿瘤药物毒副作用,主要从代谢酶及其基因多态性在抗肿瘤药物相关代谢酶的代谢激活和代谢解毒两个角度进行分析总结,以期为临床中有效规避或减少抗肿瘤药物的毒副作用,促进肿瘤的个体化治疗提供参考。
Antitumor drugs have the characteristics of low therapeutic index and narrow safety range, and are prone to toxic and side effects in the course of clinical medication, limiting their use. In recent years, some studies have pointed out that the mechanism of antineoplastic drug adverse reactions and drug metabolism enzymes, receptors and transporters, in which drug metabolizing enzymes and their genetic polymorphisms in the antitumor drug metabolism during the side effects of Important role. The author currently clinically drug-mediated metabolic drug-mediated antitumor drug side effects, mainly from metabolic enzymes and their genetic polymorphisms in the metabolism of anti-tumor drug-related metabolic enzymes metabolic detoxification and analysis of two perspectives, with a view to Effectively avoid or reduce the clinical side effects of anti-tumor drugs and promote individualized treatment of tumors provide a reference.